Navigation Links
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/23/2012

EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time.  The conference will be held at the Boston Marriott Copley Place in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.Contact:  Mary Coleman Carney Noensie Savient Pharmaceuticals, Inc. Burns McClellan information@savient.com  cnoensie@burnsmc.com (732) 418-9300  (212) 213-0006SVNT - G


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
4. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
5. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
6. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
7. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
9. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
11. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)...   Hudes Laser Aesthetica announced their ... Astanza Trinity laser and Astanza Liberty IPL technologies. ... removal, IPL hair removal, pigmented and vascular lesion ... Aesthetica is setting high standards for aesthetic clinics ... to deliver effective, long-lasting results. "Hudes ...
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., Nov. ... adherence to the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary ... and CEO, Dr. Daniel Messina. , Among the recognitions, the American College of ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, ... workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for ... . , According to the study, medical payments per claim in California decreased 4 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):